Mark C Petrie

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5427003/publications.pdf

Version: 2024-02-01

176 papers	16,385 citations	36303 51 h-index	16650 123 g-index
180 all docs	180 docs citations	180 times ranked	13977 citing authors

#	Article	IF	Citations
1	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2019, 381, 1995-2008.	27.0	4,108
2	Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. New England Journal of Medicine, 2011, 364, 1607-1616.	27.0	1,035
3	Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2010, 12, 767-778.	7.1	787
4	Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. New England Journal of Medicine, 2016, 374, 1511-1520.	27.0	731
5	Randomised controlled trial of specialist nurse intervention in heart failure. BMJ: British Medical Journal, 2001, 323, 715-718.	2.3	477
6	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 853-872.	7.1	434
7	Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. European Journal of Heart Failure, 2009, 11, 130-139.	7.1	423
8	Declining Risk of Sudden Death in Heart Failure. New England Journal of Medicine, 2017, 377, 41-51.	27.0	355
9	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA - Journal of the American Medical Association, 2020, 323, 1353.	7.4	340
10	A trial to evaluate the effect of the sodiumâ€“glucose coâ€transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPAâ€HF). European Journal of Heart Failure, 2019, 21, 665-675.	7.1	264
11	Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. New England Journal of Medicine, 2017, 376, 1956-1964.	27.0	257
12	Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2020, 141, 90-99.	1.6	244
13	A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE) Tj ETQq1 1 0.784314 rgBT /Over	13.7	238
14	Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). Circulation, 2021, 143, 516-525.	1.6	237
15	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2019, 21, 827-843.	7.1	223
16	Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]). Circulation, 2018, 137, 364-375.	1.6	206
17	A Randomized Trial of Deferred Stenting Versus Immediate Stenting to Prevent No- or Slow-Reflow in Acute ST-Segment Elevation Myocardial Infarction (DEFER-STEMI). Journal of the American College of Cardiology, 2014, 63, 2088-2098.	2.8	204
18	Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (<scp>PPCM</scp>). European Journal of Heart Failure, 2017, 19, 1131-1141.	7.1	163

#	Article	IF	Citations
19	Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2016, 18, 1096-1105.	7.1	160
20	Myocardial Hemorrhage After Acute Reperfused ST-Segmentâ€“Elevation Myocardial Infarction. Circulation: Cardiovascular Imaging, 2016, 9, e004148.	2.6	158
21	Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction. Circulation, 2017, 135, 724-735.	1.6	153
22	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 2020, 41, 2379-2392.	2.2	151
23	Heart Failure and Chronic Obstructive Pulmonary Disease. Journal of the American College of Cardiology, 2011, 57, 2127-2138.	2.8	135
24	Comparative Prognostic Utility of Indexes of Microvascular Function Alone or in Combination in Patients With an Acute ST-Segmentâ€“Elevation Myocardial Infarction. Circulation, 2016, 134, 1833-1847.	1.6	135
25	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucoseâ€lowering drugs in patients with heart failure. European Journal of Heart Failure, 2020, 22, 196-213.	7.1	131
26	Angiotensin Receptorâ€“Neprilysin Inhibition in Acute Myocardial Infarction. New England Journal of Medicine, 2021, 385, 1845-1855.	27.0	130
27	Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction. Circulation, 2016, 134, 1314-1324.	1.6	127
28	Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European Heart Journal, 2021, 42, 3727-3738.	2.2	125
29	Pathophysiology of LV Remodeling inÂSurvivors of STEMI. JACC: Cardiovascular Imaging, 2015, 8, 779-789.	5.3	116
30	Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2021, 6, 1130.	6.1	114
31	One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	3.9	113
32	Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2	13.7	112
33	Prognostic significance of infarct core pathology revealed by quantitative non-contrast in comparison with contrast cardiac magnetic resonance imaging in reperfused ST-elevation myocardial infarction survivors. European Heart Journal, 2016, 37, 1044-1059.	2.2	105
34	Longâ€term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 2018, 20, 951-962.	7.1	101
35	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. European Heart Journal, 2020, 41, 3787-3797.	2.2	101
36	Sodiumâ€“glucose coâ€transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1495-1503.	7.1	100

#	Article	IF	Citations
37	<scp>EURObservational</scp> Research Programme: a worldwide registry on peripartum cardiomyopathy (<scp>PPCM</scp>) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on <scp>PPCM</scp>. European Journal of Heart Failure, 2014, 16, 583-591.	7.1	99
38	Temporal Evolution of Myocardial Hemorrhage and Edema in Patients After Acute STâ€Segment Elevation Myocardial Infarction: Pathophysiological Insights and Clinical Implications. Journal of the American Heart Association, 2016, 5, .	3.7	96
39	Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. European Journal of Heart Failure, 2017, 19, 1723-1728.	7.1	88
40	Effects of Urotensin II in Human Arteries and Veins of Varying Caliber. Circulation, 2001, 103, 1378-1381.	1.6	87
41	Catheter Ablation for Atrial Fibrillation inÂHeart Failure Patients. JACC: Clinical Electrophysiology, 2015, 1, 200-209.	3.2	86
42	Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. European Journal of Heart Failure, 2010, 12, 17-24.	7.1	84
43	Clinical Characteristics and Outcomes of Young and Very Young Adults With Heart Failure. Journal of the American College of Cardiology, 2013, 62, 1845-1854.	2.8	84
44	Novel Diabetes Drugs and the Cardiovascular Specialist. Journal of the American College of Cardiology, 2017, 69, 2646-2656.	2.8	75
45	Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). European Heart Journal, 2014, 35, 2714-2721.	2.2	71
46	Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes and Endocrinology,the, 2015, 3, 697-703.	11.4	70
47	Discordance Between Resting and Hyperemic Indices of Coronary Stenosis Severity. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	67
48	<scp>Heart Failure Association</scp> of the <scp>European Society of Cardiology</scp> update on sodiumâ€“glucose coâ€transporter 2 inhibitors in heart failure. European Journal of Heart Failure, 2020, 22, 1984-1986.	7.1	66
49	Tissue sodium excess is not hypertonic and reflects extracellular volume expansion. Nature Communications, 2020, 11, 4222.	12.8	61
50	Diabetic cardiomyopathy. Heart, 2019, 105, 337-345.	2.9	60
51	Percutaneous Revascularization for Ischemic Ventricular Dysfunction: Rationale and Design of the REVIVED-BCIS2 Trial. JACC: Heart Failure, 2018, 6, 517-526.	4.1	59
52	The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. European Journal of Heart Failure, 2016, 18, 1491-1498.	7.1	54
53	Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure. Circulation, 2022, 145, 1592-1604.	1.6	54
54	Readmission and death in patients admitted with newâ€onset versus worsening of chronic heart failure: insights from a nationwide cohort. European Journal of Heart Failure, 2020, 22, 1777-1785.	7.1	53

#	Article	IF	Citations
55	Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. Circulation, 2022, 146, 438-449.	1.6	53
56	Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart, 2018, 104, 1995-2002.	2.9	51
57	Return to the Workforce After First Hospitalization for Heart Failure. Circulation, 2016, 134, 999-1009.	1.6	50
58	How robust are clinical trials in heart failure?. European Heart Journal, 2017, 38, ehw427.	2.2	49
59	Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the <scp>MAGGIC</scp> metaâ€analysis. European Journal of Heart Failure, 2015, 17, 1182-1191.	7.1	48
60	Importance of Angina in Patients With Coronary Disease, Heart Failure, and LeftÂVentricular Systolic Dysfunction. Journal of the American College of Cardiology, 2015, 66, 2092-2100.	2.8	48
61	Current Smoking and Prognosis AfterÂAcute ST-Segment Elevation MyocardialÂInfarction. JACC: Cardiovascular Imaging, 2019, 12, 993-1003.	5.3	46
62	Cardiotoxic effects of angiogenesis inhibitors. Clinical Science, 2021, 135, 71-100.	4.3	46
63	Remote Zone Extracellular Volume and Left Ventricular Remodeling in Survivors of ST-Elevation Myocardial Infarction. Hypertension, 2016, 68, 385-391.	2.7	44
64	The Emerging Potential of the Apelin-APJ System in Heart Failure. Journal of Cardiac Failure, 2015, 21, 489-498.	1.7	43
65	Persistent Iron Within the Infarct CoreÂAfter ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Imaging, 2018, 11, 1248-1256.	5.3	43
66	Association is not causation: treatment effects cannot be estimated from observational data in heart failure. European Heart Journal, 2018, 39, 3417-3438.	2.2	42
67	Accelerated and personalized therapy for heart failure with reduced ejection fraction. European Heart Journal, 2022, 43, 2573-2587.	2.2	41
68	Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction. Journal of the American College of Cardiology, 2022, 79, 2058-2068.	2.8	41
69	Reninâ€“angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 165-178.	3.0	40
70	Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. Circulation, 2021, 144, 199-209.	1.6	40
71	How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 506-522.	2.4	39
72	Microvascular resistance of the culprit coronary artery in acute ST-elevation myocardial infarction. JCI Insight, 2016, 1, e85768.	5.0	39

#	Article	IF	Citations
73	Comparative Significance of Invasive Measures of Microvascular Injury in Acute Myocardial Infarction. Circulation: Cardiovascular Interventions, 2020, 13, e008505.	3.9	37
74	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 2021, 23, 527-540.	7.1	37
75	Falling Cardiovascular Mortality in HeartÂFailure With Reduced Ejection Fraction and Implications for Clinical Trials. JACC: Heart Failure, 2015, 3, 603-614.	4.1	36
76	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Circulation, 2021, 143, 1962-1972.	1.6	35
77	Hypertension, Microvascular Pathology, and Prognosis After an Acute Myocardial Infarction. Hypertension, 2018, 72, 720-730.	2.7	33
78	Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction. JACC: Heart Failure, 2019, 7, 321-332.	4.1	33
79	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from <scp>DAPAâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 513-525.	7.1	33
80	Circumferential Strain Predicts Major Adverse Cardiovascular Events Following an Acute ST-Segmentâ€“Elevation Myocardial Infarction. Radiology, 2019, 290, 329-337.	7.3	32
81	Heart Failure in Young Adults Is Associated With High Mortality: A Contemporary Population-Level Analysis. Canadian Journal of Cardiology, 2017, 33, 1472-1477.	1.7	28
82	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation, 2022, 145, 87-89.	1.6	28
83	High sodium intake, glomerular hyperfiltration, and protein catabolism in patients with essential hypertension. Cardiovascular Research, 2021, 117, 1372-1381.	3.8	27
84	Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for nonâ€vitamin K antagonist oral anticoagulant dose adjustment. European Journal of Heart Failure, 2016, 18, 1162-1171.	7.1	26
85	Society of Thoracic Surgeons Risk Score and EuroSCORE-2 Appropriately Assess 30-Day Postoperative Mortality in the STICH Trial and a Contemporary Cohort of Patients With Left Ventricular Dysfunction Undergoing Surgical Revascularization. Circulation: Heart Failure, 2018, 11, e005531.	3.9	26
86	Profile of microvolt Tâ€wave alternans testing in 1003 patients hospitalized with heart failure. European Journal of Heart Failure, 2012, 14, 377-386.	7.1	25
87	Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. European Journal of Heart Failure, 2019, 21, 386-388.	7.1	24
88	Sex differences in procedural and clinical outcomes following rotational atherectomy. Catheterization and Cardiovascular Interventions, 2020, 95, 232-241.	1.7	24
89	Redefining Adverse and Reverse Left Ventricular Remodeling by Cardiovascular Magnetic Resonance Following ST-Segmentâ€“Elevation Myocardial Infarction and Their Implications on Long-Term Prognosis. Circulation: Cardiovascular Imaging, 2020, 13, e009937.	2.6	24
90	Altered diaphragm position and function in patients with chronic heart failure. European Journal of Heart Failure, 2001, 3, 183-187.	7.1	23

#	Article	IF	Citations
91	Impact of Baseline Hemodynamics on the Effects of a Transcatheter Interatrial Shunt Device in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2018, 11, e004540.	3.9	23
92	Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina. Circulation: Heart Failure, 2015, 8, 717-724.	3.9	22
93	Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. International Journal of Cardiology, 2016, 209, 310-316.	1.7	22
94	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. Circulation: Heart Failure, 2021, 14, CIRCHEARTFAILURE121008837.	3.9	21
95	Pathophysiology and risk factors of peripartum cardiomyopathy. Nature Reviews Cardiology, 2022, 19, 555-565.	13.7	21
96	Ferumoxytol-enhanced magnetic resonance imaging methodology and normal values at 1.5 and 3T. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 46.	3.3	20
97	Safety of guidewire-based measurement of fractional flow reserve and the index of microvascular resistance using intravenous adenosine in patients with acute or recent myocardial infarction. International Journal of Cardiology, 2016, 202, 305-310.	1.7	20
98	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGMâ€HF. Journal of the American Heart Association, 2021, 10, e019238.	3.7	20
99	Hypertensive disorders in women with peripartum cardiomyopathy: insights from the <scp>ESC</scp> EORP PPCM Registry. European Journal of Heart Failure, 2021, 23, 2058-2069.	7.1	20
100	Effect of sacubitril/valsartan on investigatorâ€reported ventricular arrhythmias in <scp>PARADIGMâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 551-561.	7.1	20
101	Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (<scp>STICH</scp>) trial. European Journal of Heart Failure, 2015, 17, 725-734.	7.1	19
102	Treatment strategies in ischaemic left ventricular dysfunction: a network meta-analysis. European Journal of Cardio-thoracic Surgery, 2021, 59, 293-301.	1.4	19
103	Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). European Heart Journal, 2014, 35, 3426-3433.	2.2	18
104	Combined Free Light Chains Are Novel Predictors of Prognosis in Heart Failure. JACC: Heart Failure, 2015, 3, 618-625.	4.1	18
105	Electrocardiographic features and their echocardiographic correlates in peripartum cardiomyopathy: results from the ESC EORP PPCM registry. ESC Heart Failure, 2021, 8, 879-889.	3.1	18
106	Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEKÂInhibitors. JACC: CardioOncology, 2022, 4, 1-18.	4.0	18
107	Assessment of Fractional Flow Reserve in Patients With Recent Nonâ€“ST-Segmentâ€“Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2015, 8, e002207.	3.9	17
108	Invasive Versus Medical Management in Patients With Prior Coronary Artery Bypass Surgery With a Non-ST Segment Elevation Acute Coronary Syndrome. Circulation: Cardiovascular Interventions, 2019, 12, e007830.	3.9	17

#	Article	IF	Citations
109	Persistence of Infarct Zone T2 Hyperintensity at 6 Months After Acute ST-Segmentâ€“Elevation Myocardial Infarction. Circulation: Cardiovascular Imaging, 2017, 10, .	2.6	16
110	Much Ado about Nâ€¦atrium: modelling tissue sodium as a highly sensitive marker of subclinical and localized oedema. Clinical Science, 2018, 132, 2609-2613.	4.3	16
111	Predictors of segmental myocardial functional recovery in patients after an acute ST-Elevation myocardial infarction. European Journal of Radiology, 2019, 112, 121-129.	2.6	16
112	Effects of resistive breathing on exercise capacity and diaphragm function in patients with ischaemic heart disease. European Journal of Heart Failure, 1999, 1, 297-300.	7.1	15
113	Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods. Cost Effectiveness and Resource Allocation, 2015, 13, 19.	1.5	14
114	Peripartum cardiomyopathy: diagnosis and management. Heart, 2018, 104, 779-786.	2.9	14
115	Percutaneous coronary intervention versus medical therapy in patients with angina and grey-zone fractional flow reserve values: a randomised clinical trial. Heart, 2020, 106, 758-764.	2.9	13
116	Spectral microvolt T-wave alternans testing has no prognostic value in patients recently hospitalized with decompensated heart failure. European Journal of Heart Failure, 2013, 15, 1253-1261.	7.1	12
117	Reporting of Lost to Follow-Up and Treatment Discontinuation in Pharmacotherapy and Device Trials in Chronic Heart Failure. Circulation: Heart Failure, 2016, 9, .	3.9	12
118	Cardiotoxicity and myocardial hypoperfusion associated with antiâ€vascular endothelial growth factor therapies: prospective cardiac magnetic resonance imaging in patients with cancer. European Journal of Heart Failure, 2020, 22, 1276-1277.	7.1	12
119	Adherence to prescribed medications in patients with heart failure: insights from liquid chromatographyâ€“tandem mass spectrometry-based urine analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 296-301.	3.0	12
120	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 1298-1305.	6.1	12
121	Effects of adrenomedullin on angiotensin II stimulated atrial natriuretic peptide and arginine vasopressin secretionâ€¨in healthy humans. British Journal of Clinical Pharmacology, 2001, 52, 165-168.	2.4	11
122	The shocking lack of evidence for implantable cardioverter defibrillators for heart failure; with or without cardiac resynchronization. European Heart Journal, 2019, 40, 2128-2130.	2.2	11
123	Transplantation of Hearts Donated After Circulatory-Determined Death. Circulation: Heart Failure, 2019, 12, e005991.	3.9	11
124	Who needs an implantable cardioverterâ€defibrillator? Controversies and opportunities after DANISH. European Journal of Heart Failure, 2018, 20, 413-416.	7.1	10
125	Initiation of domiciliary care and nursing home admission following first hospitalization of heart failure patients: a nationwide cohort study. Clinical Epidemiology, 2018, Volume 10, 917-930.	3.0	10
126	Novel neuropeptides in the pathophysiology of heart failure: adrenomedullin and endothelin-1. European Journal of Heart Failure, 1999, 1, 25-29.	7.1	9

#	Article	IF	Citations
127	Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 2021, 8, 129-138.	3.1	9
128	Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients. CKJ: Clinical Kidney Journal, 2022, 15, 2186-2199.	2.9	9
129	Effect of Neutral Endopeptidase Inhibition on the Actions of Adrenomedullin and Endothelin-1 in Resistance Arteries From Patients With Chronic Heart Failure. Hypertension, 2001, 38, 412-416.	2.7	8
130	Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial. Cardiovascular Research, 2020, 116, e152-e155.	3.8	8
131	EMPEROR-REDUCED reigns while EMPERIAL whimpers. European Heart Journal, 2021, 42, 711-714.	2.2	8
132	A Noncontrast CMR Risk Score for Long-Term Risk Stratification in Reperfused ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Imaging, 2022, 15, 431-440.	5.3	8
133	Effect of adrenomedullin on the production of endothelin-1 and on its vasoconstrictor action in resistance arteries: evidence for a receptor-specific functional interaction in patients with heart failure. Clinical Science, 2001, 101, 45-51.	4.3	7
134	Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABG-ACS). Open Heart, 2016, 3, e000371.	2.3	7
135	Time to Take the Failure OutÂofÂHeartÂFailure. JACC: Heart Failure, 2017, 5, 538-540.	4.1	7
136	Sex-based associations with microvascular injury and outcomes after ST-segment elevation myocardial infarction. Open Heart, 2019, 6, e000979.	2.3	7
137	Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it. European Journal of Heart Failure, 2019, 21, 699-702.	7.1	7
138	High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. Cardiovascular Research, 2023, 119, 213-220.	3.8	7
139	Stroke in hemodialysis patients randomized to different intravenous iron strategies: a prespecified analysis from the PIVOTAL trial. Kidney360, 2021, 2, 10.34067/KID.0004272021.	2.1	7
140	Importance of diagnostic setting in determining mortality in patients with new-onset heart failure: temporal trends in Denmark from 1997 to 2017. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 750-760.	4.0	7
141	Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial. Heart, 2021, 107, 299-312.	2.9	6
142	Inhibition of myocardial cathepsin-L release during reperfusion following myocardial infarction improves cardiac function and reduces infarct size. Cardiovascular Research, 2022, 118, 1535-1547.	3.8	6
143	Response by Lee et al to Letter Regarding Article, â€œEffect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)â€• Circulation, 2021, 144, e40.	1.6	6
144	PCI in Patients With Heart Failure: Current Evidence, Impact of Complete Revascularization, and Contemporary Techniques to Improve Outcomes. , 2022, 1, 100020.		5

#	Article	IF	Citations
145	Type 1 diabetes mellitus and coronary revascularization. Cardiovascular Endocrinology and Metabolism, 2019, 8, 35-38.	1.1	4
146	Ventricular Assist Devices as Rescue Therapy in Cardiogenic Shock After Subarachnoid Hemorrhage. Annals of Thoracic Surgery, 2014, 97, 1440-1443.	1.3	3
147	Mechanical circulatory support for refractory cardiogenic shock post-acute myocardial infarctionâ€"a decade of lessons. Journal of Thoracic Disease, 2019, 11, 542-548.	1.4	3
148	Prevalence and profile of â€œseasonal frequent flyersâ€•with chronic heart disease: Analysis of 1598 patients and 4588 patient-years follow-up. International Journal of Cardiology, 2019, 279, 126-132.	1.7	3
149	Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure, stroke, chronic obstructive pulmonary disease or cancer. PLoS ONE, 2021, 16, e0255364.	2.5	3
150	Coronary angiography in heart failure: when and why? Uncertainty reigns. Heart, 2018, 104, 548-549.	2.9	2
151	Ferumoxytol-enhanced MRI in patients with prior cardiac transplantation. Open Heart, 2019, 6, e001115.	2.3	2
152	Sodium Glucose Cotransporter 2 Inhibitors. Circulation, 2019, 140, 1703-1705.	1.6	2
153	Sodiumâ€“glucose coâ€transporter 2 inhibitorsâ€"the first successful treatment for heart failure with preserved ejection fraction?. European Journal of Heart Failure, 2021, 23, 1256-1259.	7.1	2
154	Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure. Heart, 2022, 108, 312-320.	2.9	2
155	Reninâ€“angiotensinâ€“aldosterone inhibitors and <scp>COVID</scp>â€19: nearing the end of a mediaâ€fuelled controversy. European Journal of Heart Failure, 2021, 23, 486-488.	7.1	2
156	Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populations. Open Heart, 2021, 8, e001453.	2.3	2
157	Reflections on the Danish Revolution. European Heart Journal, 2004, 25, 540-542.	2.2	1
158	CABG or PCI for Diabetic Patients WithÂLeft Ventricular Dysfunction. Journal of the American College of Cardiology, 2018, 71, 828-831.	2.8	1
159	Implantable cardioverterâ€defibrillators and survival â€“ the fine line between efficacy concerns and ageism. European Journal of Heart Failure, 2020, 22, 868-870.	7.1	1
160	Six-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathy. Open Heart, 2018, 5, e000752.	2.3	1
161	Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populations. Open Heart, 2021, 8, .	2.3	1
162	I'm Sorry Mr Paxman!. Scottish Medical Journal, 2005, 50, 149-150.	1.3	0

#	Article	IF	Citations
163	Diabetes, Left Ventricular Systolic Dysfunction and Chronic Heart Failure. , 0, , 93-134.		0
164	Feasibility/eligibility of Tâ€wave alternans testing in patients with heart failure: should we rethink our current modus operandi?: reply. European Journal of Heart Failure, 2012, 14, 676-677.	7.1	0
165	Microvolt Tâ€wave alternans testing should be used to guide arrhythmic therapy in heart failure patients: reply. European Journal of Heart Failure, 2012, 14, 678-678.	7.1	0
166	109â€…Left Ventricular Outcomes Following Multivessel PCI Vs. Infarct -Only PCI in Patients with Acute Stemi: The Glasgow Prami CMR Sub-Study: Abstract 109 Table 1. Heart, 2015, 101, A62.2-A62.	2.9	0
167	110â€…Infarct Burden Following Multivessel PCI Vs. Infarct-Only PCI in Patients with Acute Stemi: The Glasgow Prami CMR Sub-Study: Abstract 110 Table 1. Heart, 2015, 101, A63.1-A63.	2.9	0
168	115â€…Persistence of Infarct Zone Oedema at 6 Months after Acute ST-elevation Myocardial Infarction: Incidence, Pathophysiology and Association with Left Ventricular Remodelling. Heart, 2016, 102, A81.2-A81.	2.9	0
169	114â€…Persistence of Haemoglobin Degradation Products within Infarct Scar Tissue after ST-elevation Myocardial Infarction: Incidence, Correlates and Implications for Left Ventricular Remodelling. Heart, 2016, 102, A81.1-A81.	2.9	0
170	2â€…Coronary flow reserve and index of microvascular resistance in acute stemi. Heart, 2016, 102, A1.2-A1.	2.9	0
171	9â€…Routine non-invasive vs invasive management in patients with prior CABG with a NSTE-ACS: a randomised controlled trial. , 2018, , .		0
172	Response to the letter regarding the hypothesis paper â€œMuch ado about Nâ€¦atrium: modelling tissue sodium as a highly sensitive marker of subclinical and localised oedemaâ€• Clinical Science, 2019, 133, 761-761.	4.3	0
173	OP10â€…Skin Na⁺ excess in hypertensive patients: isotonic nature and clinical correlates. , 2020, , .		0
174	Low-dose intracoronary alteplase during primary percutaneous coronary intervention in patients with acute myocardial infarction: the T-TIME three-arm RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-86.	0.7	0
175	Impacts of Changing Post-harvest Agricultural Practices on Abundance of Waste GrainÂin Californiaâ€™s Central Valley. Journal of Fish and Wildlife Management, 0, , .	0.9	0
176	Diagnostic and prognostic value of the electrocardiogram in stable outpatients with type 2 diabetes. Scandinavian Cardiovascular Journal, 2022, 56, 256-263.	1.2	0